Antimicrobial resistance: Concerns of healthcare providers and people with CF
18 June 2020
Chronic lung infections and their treatment pose risks for the development of antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated the attitudes of healthcare providers’ (HCP) and PWCF or their parents’ toward AMR within the international CF community.
These results highlight that AMR is relevant to CF HCP and PWCF internationally, indicating that educational tools and research are warranted.
Further reading: Journal of Cystic Fibrosis
Author(s): Wendy Bullington, Sarah Hempstead, Alan R. Smyth, Pavel Drevinek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. Van Devanter, Patrick A. Flume, Stuart Elborn, Marianne S Muhlebach
Healthy Patients
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
